Loading
A phase 2/3 trial of rozanolixizumab in childhood cancers, run by UCB Biopharma SRL, active and no longer recruiting.
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis is a phase 2/3 interventional study registered as NCT06149559 by UCB Biopharma SRL, with 14 participants enrolled, started 2024-06-14 and due to reach its primary completion in 2026-10-05. Interventions recorded: rozanolixizumab.
Shares UCB, Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.